Form 8-K - Current report:
SEC Accession No. 0001564590-20-011831
Filing Date
2020-03-19
Accepted
2020-03-19 17:18:53
Documents
12
Period of Report
2020-03-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K arwr-8k_20200314.htm   iXBRL 8-K 69939
  Complete submission text file 0001564590-20-011831.txt   202438

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA arwr-20200314.xsd EX-101.SCH 5812
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20200314_lab.xml EX-101.LAB 19478
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20200314_pre.xml EX-101.PRE 11657
5 EXTRACTED XBRL INSTANCE DOCUMENT arwr-8k_20200314_htm.xml XML 3565
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 20729372
SIC: 2834 Pharmaceutical Preparations